Biotech Values

[linhdtu]

I have to agree with you. As far as investing in HCV companies, perhaps they have seen the top which was driven by expectation ofexpanding revenues in rich countries which has proven to be wrong.
One simply can't charge high enough in poor countries.
From now on, it is a matter of who has the best 2nd gen overall. As for enta, a double from here depends on nash and not hcv.